Events

SERA PROGNOSTICS TO PRESENT AT THE BTIG VIRTUAL MEDTECH, DIGITAL HEALTH, LIFE SCIENCE & DIAGNOSTIC TOOLS CONFERENCE

February 15, 2021 — Sera Prognostics, Inc., a leading health diagnostics company dedicated to improving the lives of women and babies through individualized prenatal care, will be presenting at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Sera’s presentation will take place on Wednesday, February 17 from 3:30 to 3:55PM (ET) and will be available for registered attendees of the conference. Gregory C. Critchfield, M.D., M.S., Chairman and CEO, will provide a company update and discuss Sera’s latest achievements. Sera’s management will be available for one-on-one meetings with conference attendees on February 17.

About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through individualized prenatal care. Sera delivers pivotal information to physicians to improve health and to improve the economics of healthcare delivery for pregnant women. Sera is developing innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® test objectively reports to a physician the risk of a woman’s premature delivery, enabling earlier proactive interventions designed to improve the health of her baby. Sera is working with other researchers to demonstrate the impact of additional interventions to improve pregnancy outcomes when used in connection with the PreTRM® test to stratify risk of prematurity.  Sera Prognostics is located in Salt Lake City, Utah. For more information, please visit the company’s website at www.seraprognostics.com.

About the PreTRM® Test
The PreTRM® test is the only broadly clinically-validated blood test that provides an early and individual risk prediction for spontaneous preterm birth in asymptomatic, singleton pregnancies. The PreTRM® test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM® test can help physicians identify early in the pregnancy (as early as 19 weeks of gestation) which women are at increased risk for premature delivery, enabling more informed clinical decisions based on each woman’s individual risk. The PreTRM® test is ordered by a medical professional. For more information about the PreTRM® test, please visit www.PreTRM.com and the PreTRM® test YouTube Channel. You can also join the conversation on Facebook and @PreTRM on Twitter.

SERA PROGNOSTICS TO PRESENT AT THE 40TH ANNUAL WILLIAM BLAIR GROWTH STOCK CONFERENCE

June 5, 2020 — Sera Prognostics, Inc., The Pregnancy Company®, the leading health diagnostics company dedicated to improving the lives of women and babies through individualized prenatal care, today announced that it will present at the 40th Annual William Blair Growth Stock Conference on June 11, 2020.

Gregory C. Critchfield, M.D., M.S., Chairman and CEO, will discuss Sera’s latest achievements and upcoming clinical data read-outs. Sera’s management will be available for one-on-one meetings with conference attendees after the presentation.

About Sera Prognostics, Inc.
Sera Prognostics is the leading health diagnostics company dedicated to improve the lives of women and babies through individualized prenatal care. Sera delivers pivotal information to physicians to improve health and to improve the economics of healthcare delivery for pregnant women. Sera is developing innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® test objectively reports to a physician the risk of a woman’s premature delivery, enabling earlier proactive interventions designed to improve the health of her baby. Sera is working with other researchers to demonstrate the impact of additional interventions to improve pregnancy outcomes when used in connection with the PreTRM® test to stratify risk of prematurity.  Sera Prognostics is located in Salt Lake City, Utah. For more information, please visit the company’s website at www.seraprognostics.com.

About the PreTRM® Test
The PreTRM® test is the only clinically-validated blood test that provides an early and individual risk prediction for spontaneous preterm birth in asymptomatic, singleton pregnancies. The PreTRM® test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM® test can help physicians identify early in the pregnancy (as early as 19 weeks of gestation) which women are at increased risk for premature delivery, enabling more informed clinical decisions based on each woman’s individual risk. The PreTRM® test is ordered by a medical professional. For more information about the PreTRM® test, please visit www.PreTRM.com and the PreTRM® test YouTube Channel. You can also join the conversation on Facebook and @PreTRM.

Society for Maternal-Fetal Medicine’s (SMFM) 2020 Annual Pregnancy Meeting

Date: February 3-8, 2020
Location: Dallas, TX

Society for Reproductive Investigation (SRI) 2019 Annual Meeting

Date: March 12-16, 2019
Location: Paris, France

Society for Maternal-Fetal Medicine’s (SMFM) 2019 Annual Pregnancy Meeting

Date: February 11-16, 2019
Location: Las Vegas, NV

International Federation of Gynecology and Obstetrics (FIGO) World Congress

Date: October 14-19, 2018
Location: Rio de Janeiro, Brazil

Society for Reproductive Investigation (SRI) 2018 Annual Meeting

Date: March 6-10, 2018
Location: San Diego, CA

Society for Maternal-Fetal Medicine’s (SMFM) 2018 Annual Pregnancy Meeting

Date: Jan 29 – Feb 3, 2018
Location: Dallas, TX

2017 American College of Obstetricians and Gynecology (ACOG) Annual Meeting

Date: May 6-9, 2017
Location: San Diego, CA

2017 American College of Nurse-Midwives (ACNM) Annual Meeting

Date: May 21-25, 2017
Location: Chicago, IL